HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for ...

NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 —— ...
Grit Daily

How Developers Build High-Performing Shopify Stores

Most businesses rely on online platforms to connect with their customers. Shopify is reliable and adaptable if you plan to ...